OSE Immunotherapeutics Reports First Half 2025 Financial Results

OSE Immunotherapeutics Reports First Half 2025 Financial Results

NANTES, France, October 15, 2025 – 7:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today reported its consolidated financial results for the first half of 2025.

The half-year financial statements for 2025 were subject to a limited review by the Company’s statutory auditors and were approved by the Board of Directors on October 15, 2025.

2025 Half-Year Financial Results (IFRS)

In million euros	H1 2024	H1 2025
Revenues	69.0	1.3
Other income	13.5	0.0
Operating income	82.6	1.4
Research and development expenses	(13.9)	(14.8)
General and administrative expenses	(4.3)	(4.5)
Share-based payments expenses	(1.1)	(2.2)
Other operating items	-	4.4
Operating profit (loss)	63.3	(15.8)
Financial income (loss)	(2.6)	0.8
Net income (loss)	57.2	(15.1)
EPS (in € per share)	2.63	(0.68)
Net cash flows from operating activities	66.4	(19.2)
Net cash flows from investment activities	(54.9)	30.4
Net cash flows from financing activities	(4.3)	(2.5)
Net cash flows	7.2	8.6
Cash and cash equivalents at closing	25.9	25.4
Total Cash Position at closing (incl. long-term deposits)	64.2	41.6

Operating income for the first half of 2025 amounted to €1.3 million, primarily reflecting the deferred recognition of a portion of the $48 million upfront payment from the AbbVie licensing agreement on OSE-230 signed in April 2024 for €0.7 million, and revenues generated by Tedopi’s early access program in France for €0.4 million. In comparison, operating income for the first half of 2024 totaled €82.6 million, driven mainly by the immediate booking of the majority of the AbbVie upfront payment for €42.2 million, €25.3 million from the amendment to the agreement with Boehringer Ingelheim on BI 765063 (OSE-172), and €13.5 million from the asset purchase by Boehringer Ingelheim related to the “cis-targeting” anti-PD1/cytokine platform.